Status:
UNKNOWN
Oral Vitamin D and Toll Like Receptor in Spondylitis Tuberculosis
Lead Sponsor:
Hasanuddin University
Conditions:
Spondylitis
Tuberculosis
Eligibility:
All Genders
19-50 years
Phase:
PHASE2
PHASE3
Brief Summary
Background : The toll-like receptor is an essential receptor that stimulates the innate immunity response. In tuberculosis, toll-like receptors, particularly the TLR-2, and TLR-4 are crucial in recog...
Detailed Description
Target population: Patients with spondylitis tuberculosis without the involvement of lung and other extrapulmonary infection Design: Randomized Clinical Trial with 3 arms Primary Intervention: St...
Eligibility Criteria
Inclusion
- Diagnosed as Spondylitis Tuberculosis (Clinically and Laboratory confirmed)
- Level of Total Vitamin D \<50 nmol/L at baseline
Exclusion
- Participants with pulmonary tuberculosis or other extrapulmonary tuberculosis
- Participants with osteoporosis, malignancy, cardiovascular disease, diabetes mellitus, and autoimmune disease
- Participants with liver and kidney dysfunction
- Participants who received Vitamin D prior to enrollment
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2023
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT05376189
Start Date
July 1 2022
End Date
February 1 2023
Last Update
May 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wahidin Sudirohusodo General Hospital
Makassar, South Sulawesi, Indonesia, 76124